Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $747,375.11 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 45,767 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,094,354.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28.
• On Monday, August 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.47, for a total value of $3,110,985.36.
• On Wednesday, July 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00.

Hims & Hers Health Stock Up 0.7 %

Shares of Hims & Hers Health stock traded up $0.11 during trading on Monday, hitting $16.41. 3,947,375 shares of the company were exchanged, compared to its average volume of 7,744,376. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $25.74. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -1,646.00 and a beta of 1.05. The firm has a 50 day moving average price of $17.35 and a 200 day moving average price of $17.09.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the firm posted ($0.03) EPS. The company’s quarterly revenue was up 51.8% compared to the same quarter last year. Analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HIMS. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Truist Financial lifted their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, Bank of America lowered their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $19.86.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HIMS. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the last quarter. Cim LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at $1,445,000. Sanctuary Advisors LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at $415,000. Creative Planning acquired a new position in Hims & Hers Health in the 2nd quarter valued at $443,000. Finally, Scientech Research LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at $1,474,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.